{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nexavar&page=6",
    "query": {
      "intervention": "Nexavar",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 327,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nexavar&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nexavar&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T23:55:16.333Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01032850",
      "title": "Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sorafenib & Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2009-09",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2021-06-02",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 3,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01032850"
    },
    {
      "nct_id": "NCT00300885",
      "title": "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small Cell Lung"
      ],
      "interventions": [
        {
          "name": "Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin plus Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 926,
      "start_date": "2006-02",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 80,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00300885"
    },
    {
      "nct_id": "NCT00326898",
      "title": "Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Stage I Renal Cell Cancer AJCC v6 and v7",
        "Stage II Renal Cell Cancer AJCC v7",
        "Stage III Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1943,
      "start_date": "2006-04-24",
      "completion_date": "2021-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 966,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 601 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326898"
    },
    {
      "nct_id": "NCT00865709",
      "title": "Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2009-03",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2014-12-11",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 5,
      "location_summary": "Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Brockton",
          "state": "Massachusetts"
        },
        {
          "city": "Burlington",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865709"
    },
    {
      "nct_id": "NCT00984282",
      "title": "Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Neoplasms"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar, BAY43-9006)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 417,
      "start_date": "2009-10-15",
      "completion_date": "2017-08-30",
      "has_results": true,
      "last_update_posted_date": "2018-09-13",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Stanford, California • New Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00984282"
    },
    {
      "nct_id": "NCT00589550",
      "title": "PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "PEG-interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Thomas Olencki",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2008-02",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589550"
    },
    {
      "nct_id": "NCT00255658",
      "title": "Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-09",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2015-04-15",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00255658"
    },
    {
      "nct_id": "NCT02298348",
      "title": "Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-10-08",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02298348"
    },
    {
      "nct_id": "NCT00448149",
      "title": "Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2006-12",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2016-03-17",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448149"
    },
    {
      "nct_id": "NCT02015728",
      "title": "Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Recurrent Childhood Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Tumor biology testing",
          "type": "DEVICE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Month to 30 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-12",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-11-18T23:55:16.333Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02015728"
    }
  ]
}